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Abstract
Social phobia is a newly defined disorder, and treatments for it typically
involve pharmacotherapy or some form of in vivo exposure. When combining
these therapies, there are three possible outcomes: No effect, an additive
effect, or an interference effect. If additive, the pharmacotherapy will
enhance the extinction of fear, and it will not increase the chance of
relapse after drug discontinuation. If there is an interference effect,
the pharmacotherapy will block extinction to the phobic situation, and
there will be a relapse of anxiety when placed in the phobic situation
in the no drug state. If this is the result, it may be due to
state-dependent learning. This study tested to see what effect the combining
of a placebo or alprazolam with guided exPOsure would have on subjective
measures of anxiety for a socially phobic patient, and to see if
state-dependent learning would be present in the alprazolam + exposure
condition. Results suggest that there was state-dependent learning in
the alprazolam + exposure condition, and that fear extinction was greater
in the placebo + exposure condition.
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State-Dependent Learning During Alprazolam Assisted Exposure:
A pilot Study of Social Phobia
Social phobia is a relatively new disorder, having first been described
by Marks and Gelder (1966), and not having been formally recognized in
the United States until 1980, with the publication of the Diagnostic
and Statistical Manual-III (DSM-III) (American Psychiatric Association,
1980). As stated in DSM-IIIR (the revised third edition) (American
Psychiatric Association, 1987), social phobia is "a persistent fear of
one or more situations ... in which a person is exposed to possible scrutiny
by others (p. 243)." Typical examples of social phobia are the fear of
using public restroams, writing or eating in front of PeOple, and speaking
in public. While in these situations, the social phobic fears embarrassing
or humiliating himself.
Further criteria used to diagnose social phobia are 1) the person
typically avoids or painfully endures a feared situation, 2) the avoidance
interferes with social or occupational functioning, and 3) the person
recognizes that the fear is excessive. Also, there may not be any relation
to another Axis I (non-developmental) or Axis III (physical) disorder
(American Psychiatric Association, 1987, p. 243).
In a recent review by Scholing and Emmelkamp (1990), social phobia's
prevalence in the general population has been reported at ranges from
.9% to 1.7% for males and 1.5% to 2.6% for females. It is also reported
that studies of the age of onset suggest social phobia typically begins
between the ages of 16 to 21 years old.
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As

reviewed by Barlow (1988), the treatment receiving the rrost

empirical support for this disorder is in vivo exposure to the feared
situation. Several researchers have reported that patients exposed to
anxiety-evoking stimuli had higher rates of improvement on nearly all
psychological measures than did those instructed to avoid anxious situations
(Butler, 1985; Greist, Marks, Berlin, Gournay, & Noshirvani, 1980).
Another study found that a group of social phobics exposed to their
anxiety provoking or "phobic" situations fared better in post-test and
3 and 6-rronth follow-up tests than those in a waiting list control group
(Butler, CUllington, Munby, Aimes, & Gelder, 1984). In a review by Marks
(1985), studies confirm that the beneficial effects of exposure are
maintained up to nine rronths after treatment completion. Exposure can
either be encouraged, which has the patient do it on his own, or it can
be guided by the therapist.
The mechanism of action through which exposure has been hypothesized
to work is an extinction of the phobic response. "Extinction refers to
decrements in the strength of learned responses through repetition of
unreinforced responding" (Barlow, 1988, p. 289). Thus, patients learn
that while exposed over and over to the feared situation, the feared
consequence will not occur. This process is rePeated until the patient
can enter the situation with no maladaptive rise in anxiety. Exposure
is not a quick relief therapy. Although it takes time to complete, it
appears to have lasting effects.
Pharmacotherapy is another widely used treatment for anxiety disorders

-
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(Barlow, 1988; Mavissakalian, 1982; Barlow & Mavisakalian, 1981). One
class of medications that may be used are the benzodiazepines, such as
alprazolam, a triazolobenzodiazepine (Mavissakalian, 1982). Alprazolam
has shown consistent anti-anxiety effects, it is relatively safe, and
it is quick acting (often in a matter of days anxiety will be subdued).
But, even on slow tapered schedules, relapse rates are still high, with
some studies finding as high as 90% relapse (Barlow, 1988).
A third direction for research in the treatment of anxiety disorders
is to investigate combinations of behavior therapy and pharmacotherapy
(TeIch, 1988). When combining these treatments, there are three possible
outcomes. One, the combined treatments may show no difference in outcome
ratings than one or the other treatments alone. If this is the result,
then there is no need to combine the treatments. Two, there may be an
additive effect in that both therapies are beneficial to the subject
and they do not interfere with the other's mechanism of action, and there
should be low relapse rates after the treatment is discontinued. If this
is the outcome, the drug will have allowed for quick suppression of anxiety
while the behavior therapy, which is known to have lasting effects due
to extinction of the phobic response, will have been learned with no
interference. Or three, there may be a negative effect; one of the two
therapies may interfere with the other and inhibit its mechanism of action,
and there may be a high relapse rate after treatment is discontinued.
If this is the result, it is likely that the drug somehow interfered
with the extinction process of the behavior therapy (TeIch, 1988).
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Additive effects have been supported for tricyclic antidepressants.
For example, Mavissakalian, Michelson, and Dealy (1983), found that
imipramine combined with programmed practice was much more effective
in the treatment of agoraphobia than was imipramine alone. They and others
later found that imipramine enhanced the effects of exposure therapy
for agoraphobics (Cox, Ballenger, Laria, Hobbs, Peterson, & Hucek, 1988;
Mavissakalian & Michelson, 1986).
In a review article, Wardle (1990) found that in five out of six
anxiety disorder studies which she compared, the benzodiazepine + exposure
groups had higher or equal outcome measure ratings to the no drug or
placebo groups.
Despite these findings, authors are still calling for more research
on combined treatments (Wardle, 1990; Gray, 1987; Leibowitz, Gorman,
Fyer, & Klein, 1985). This is partially due to few studies found in the
literature having benzodiazepines combined with exposure (Wardle, 1990),
and also due to evidence of benzodiazepine's interference effects. Gray
(1987), found that "under some conditions, anxiolytic drugs are able
to directly and completely block the process by which exposure to an
anxiogenic event creates behavioral tolerance for that event (p. 439)."
One potential interfering mechanism is the phenomenon known as
state-dependent learning, which is the learning or storage of a set of
behaviors in one state, such as while on alprazolam, and the later retrieval
and testing of that behavior in the same or different state (Weingartner,
1978). What is learned while on a drug may not transfer to the no drug
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condition. While a dispute continues over how state-dependent learning
occurs, there is research to support its existence.
In an experiment of fear extinction in rats with the two
benzodiazepines chlordiazepoxide and diazepine, it was found that when
extinction was combined with one of the benzodiazepines, it was relatively
ineffective at reducing fear in the drug free state. The rats in the
combined treatment exhibited more freezing (fear) behavior than those
in the no drug (extinction only) condition (Bouton, Kenny, & Rosengard,
1990).
One study done with humans found that in an alprazolam + exposure
treatment program for panic disorder with agoraphobia, high-dose alprazolam
significantly impaired post-exposure gains when the drug was discontinued,
but not while patients were still on the drug (Marks, Swinson, Basoglu,
Kuch, Noshirvani, O'Sullivan, Lelliot, Kirby, Mc Namee, Sengun, & Wickwire,
in press). The exposure alone group showed improvement even through
follow-up.
However, a similar study. found differing results (Bruce, Spiegel,
Falkin, & Nuzzarello, 1992). Bruce et al. (1992), found that an alprazolam
+ Panic Control Therapy group did not have significantly impaired gains

after alprazolam was tapered. The combined treatment group actually fared
better than the drug only group on discontinuation outcomes.
With these differing results, it can be seen that there are no
conclusive studies directly investigating the role of state-dependent
learning while under the influence of alprazolam in humans. Further,

•
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I am personally not aware of any studies comparing alprazolam + guided
exposure to placebo + guided exposure for social phobia. However, a study
has recently been published in which alprazolam was combined with
encouraged exposure for social phobia (Gelernter, Uhde, Cimbolic, Arnkoff,
Vittone, Tancer, & Bartko, 1991). Gelernter et al. (1991) concluded that
when combined with encouraged exposure, alprazolam is an effective treatment
for social phobia.
Therefore, this study had two goals: 1) to see if alprazolam would
facilitate or interfere with guided exposure both within and between
sessions, and 2) to see if there would be any evidence of state-dependent
learning in the alprazolam + exposure condition. This was done by comparing
the subjective units of distress (SUDS) ratings for exposure to a task
while under the influence of alprazolam, and then re-exposing the patient
to the same task two days later (giving the drug time to wash out of
his system).
I predicted that the alprazolam + exposure conditions would have
a lower rating of anxiety than the placebo + exposure conditions due
to the fact that alprazolam is a fast acting benzodiazepine, and would
therefore quickly reduce anxiety in the subject. I also predicted that
there would be state-dependent learning. I felt that the drug effect
will be similar to that of alcohol. While people typically "loosen-up"
after several drinks, I predicted that the subject would be affected
in a similar manner, and he would be able to perform the exposure tasks
with relative ease. But, after the drug was washed out, I predicted that
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the subject would be at the same anxiety level that he was at previous
to drug ingestion.
Method
Subject
The subject for this study was a 25 year old socially phobic male,
as defined by DSM-IIIR criteria. His social phobia was of the generalized
type. He was referred to the University of Illinois College of Medicine
at Peoria (UICOMP) in 1989 for the treatment of social phobia with secondary
depression. That is, his depression was a consequence of his fear of
social situations. Because of its severity, the depression was treated
first. The subject has since overcome his depression, and has entered
treatment for social phobia. He agreed to participate in this study as
part of a clinical assessment to determine if his exposure therapy should

be assisted by medication.
Apparatus
All exposures were recorded through a one-way mirror. A Panasonic
video camera and hidden microphone were used to record all six sessions.
Ratings of anxiety were taken using a 0-100 Likert type rating scale
of subjective units of distress (SUDS). The ratings were taken before,
during (at approximately thirty second intervals), and after
the exposure session.
Procedure
This exPeriment lasted for 13 consecutive days, with the subject
completing what will be termed six "units" of exposure to six differing

•
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tasks. Each unit consisted of six exposures, termed trials, to a given
task.
On

the morning of the first session, the subject was oriented to

the self-rating scales to be used during the exposure sessions. Then,
exposure to the first task (Task A) began. This first exposure was used
to obtain a baseline value of anxiety for that particular task.
After the first exposure to Task A, the subject was given either
.5 mg. of alprazolam, or an indistinguishable placebo pill. This was
done in a double-blind fashion. Which pill the subject received was
determined randomly, with three alprazolam and three placebo pills having
been given out

ove~

the six exposure sessions.

Exposure to Task A took place three more times, beginning one hour
after the ingestion of the pill. This length of time allowed for peak
blood concentration of alprazolam (Paul, 1985).
Prior to the second exposure trial (the first exposure after the
ingestion of the pill), the subject was asked if he thought he had taken
alprazolamor not. This was done to see if the subject could predict
whether or not he was medicated, and i f he could, whether it would affect
his exposure SUDS. After the three exposures, the subject was instructed
to corne back in the morning two days from then to continue the assessment.
He was instructed not to practice the task that he had been exposed to.
The third day began with two more exposures to Task A. This was
the test for state-dependence, since the drug had had adequate time to
wash out of the subjects system.

•
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The end of the last exposure to Task A marked the end of the first
unit. The subject was then exposed to Task B. This cycle was continued
until all six units were completed. The tasks were arranged in a hierarchy
from least to most anxiety provoking.
Design
An

alternating treatment design was used in this study. This design

was optimal because it allowed for a rapid, random alteration of the
two conditions, and for easy comparison of the effects of the conditions.
Human Subject
The subject had consented to participating in the assessment
experiment, and had signed all necessary forms and doctnnents before exposure
began. All data were kept anonymous and confidential. At the end of the
study, the subject was debriefed and placed into a treatment program
for social phobia that was modeled after the optimal treatment phase
from this study.
Treatment Integrity
The degree to which the exposure and medication protocols were
delivered was assessed via content delivery checks of the recordings
made of the sessions. All of the sessions were videotaped, and 50% were
reviewed for treatment integrity. Those sessions reviewed were rated
for compliance with the treatment protocol on a 0 - 100 Likert scale
developed at the clinic. The therapist was rated for inappropriate
verbalizations (e.g. topics irrelevant to active therapy, or particular
to alternate therapies) as well.
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Compliance with the medication protl)Col was confirmed by having
the subject ingest the designated pill in front of the therapist one
hour before exposure began.
Results
To examine whether SUDS scores decreased as a function of tbne
(hab~tuation),

thus confounding

r~sults,

the percent change from baseline

for the average of trials two, three, and four (active exposure therapy)
of each unit was computed and graphed by condition in the order that
they were presente3 to the subject (see Figure 1). The average percent
change score remained around 50% for the first five trials, and was around
40% for

L~e

sixth trial. This consistency of response suggests that learning

occurring to one task did not generalize reliably to others and result
in gradual habituation as a function of time. Further, if habituation
were to have occurred, there would have been an increase in percent change
from baseline scores, and not a decrease as seen in the sixth trial.

Insert Figure 1 about here

Credibility
Prior to treatment, the subject was asked to rate the following
question on a 0 - 100 scale; "How reasonable do you feel the treatment
protocol is?". He gave the protocol a 100% credibility rating. After
the study was completed, he was asked if he would recornnend this prob)Col
for a friend with social phobia, and he replied that he would.
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Treatment Integrity
As described earlier, 50% of the exposure sessions were checked

for treatment integrity. The results indicate that there were no integrity
violations. Further, there were no instances of the medication protocol
being violated. Thus, it appears that both the pharmacotherapy and exposure
therapy were delivered distinctly and as intended.
Also, the patient guessed which pill had been administered to him
only 44% of the time, or one correct guess above random (In the entire
study done at UICOMP, there was also a beta-blocker condition which was
not reported in this study. In the entire study there were nine units,
and the subject guessed which pill had been administered only four times.).
Thus, it appears that the subject was unable to predict whether he was
medicated or had taken a placebo pill.
To

test whether the conditions differed during exposure, the SUDS

from the six units were averaged by condition and graphed per trial (see
Figures 2

&

3). Based on the SUDS scores for day one, it can be seen

that there was a large initial drop of SUDS levels in the alprazolam
+ exposure condition (AEC) after drug ingestion, while it was much more

gradual in the placebo + exposure condition (PEC). The latencies were
also considerably shorter for the first two pill + exposure trials of
the AEC than for the PEe (exposure would end when three consecutive SUDS
ratings of 10 were given during exposure). However, by trial four, both
conditions had similar scores and latencies.
To

test for possible interference effects, trials five and six (day
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three results) can be graphically canpared. There was rroderate rebound
in both conditions for the fifth trial (the first test of state-dependent
learning), and a return to non-baseline exposure norms in trial six.
One notable effect in the graphs is that day three latencies for the
AEC were twice as long as they were for the PEC.

Insert Figures 2 & 3 about here

Tb test whether conditions differed during exposure relative to
baseline, SUDS scores were converted to a percentage change from baseline
value. This allowed for comparisons of conditions without the effect
of varying baseline unit scores (see Figures 4 & 5). Percent change from
baseline values for mean scores (average mean of the three units in each
condition per trial) and maximum scores (average maximum score of the
three units in each condition per trial) of trials two and three show
that the AEC had a greater initial reduction of anxiety than the PEC.
By the fourth trial, the PEC is shown to have had the greatest percent
change from baseline.
For the fifth trial (the first check for state-dependent learning),
both conditions rebounded, or approached near baseline levels. At the
sixth trial (the second check of state-dependent learning), both average
percent change scores are near the highest average Percent change scores
(those of trial four) again for mean score averages. For maximum score
averages at trial six, however, the AEC percent change score does not
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even equal that of trial two (the lowest percent change score while
medicated), while the PEC score is near that of trial four.

Insert Figures 4 & 5 about here

Discussion
Any bias or expectancy effects affecting this study are unlikely,
as the blind was kept, and the subject guessed only one above random
as to whether he had taken a placebo or one of the medications. The
treatment protocol was highly credible to the patient, and treatment
was deliveJ::-ed distinctly and as intended. Also, there were no order or
habituation effects that confounded the outcome of the study.
The first hypothesis, that alprazolam would decrease anxiety quicker
than the placebo was confinued. The ABC did have quicker reductions of
anxiety than the PEe did. By the fourth trial though, the PEC had lower
ratings of anxiety than the AEC did.
The second hypothesis was that there would be state-dependent learning.
An interference effect was evidenced by the large rebounds of each condition
between trials four and five. The evidence supporting that state-dependent
learning occurred in the AEC are the longer latencies for trials five
and six on day three canpared to those of the PEe (see Figures 2

&

3),

and also the relatively low percent change fram baseline for average
max~um

trial score on trials five and six (see Figure 5).

One possibility for the large amount of rebound in both conditions
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on day three is that there were attributional effects. Since there was
no pill given for either condition in the fifth and the sixth trial,
the subject had to overcome the external attribution of not taking a
pill on these trials. With a return to near high r::ercent change from
baseline average scores (mean and maximum) in the sixth trial of the
PEC condition, it seems that it only took one trial to overcome this.
But, the AEC also had to overcome the internal attribution of being
medicated. Looking at the r::ercent change from baseline for maximum scores
for the AEC, it seems that this was not overcome by trial six.
The strength of this study was that it had good internal validity.
The treatment was highly credible and integrity was good. Also, it allowed
for easily defined trends on how either alprazolam or the placebo interacted
with exposure therapy.
This study did have some weaknesses though. There was low external
validity due to the attributional effects of no pill being given in trials
five and six. Also, the procedure used in this study was very time
consuming.

sane implications can be drawn from this study. It can be seen that
interference can occur when canbining treatments. Therefore, there is
a need for designs that can effectively canbine the quick relief of anxiety
that pharmacotherapy has been shown to give with the lasting effects
that behavior therapy has been known to achieve. One way to do this is
to use a design similar to Spiegel et ale (1992). There, pharmacotherapy
and exposure therapy were given simultaneously, and exposure did not
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end with alprazolam discontinuation, but lasted for several weeks following
discontinuation. Therefore, even if there was some state-dependent
interference from the drug, it was overcome by a continuing of exposure
through and after drug discontinuation. The drug was also useful in helping
those who were very frightened of exposure, because it calmed them
initially. As the drug was discontinued and exposure was continued, the
calming effects lost due to a decrease in alprazolam were compensated
by the increased confidence instilled by the behavior therapy. This is
in opposition to the Marks et al. (in press) study which discontinued
high does alprazolam and exposure therapy simultaneously. This design
seems to have maximized the chance for relapse, since almost every patient
relapsed after discontinuation. With no further exposure after drug
discontinuation, interference was not compensated for.
Future studies will have to rule out attributional effects. This
can be done by giving a pill to future subjects during all trials, but
varying the active drug. Also, one or two more trials (trial seven and
possibly trial eight) will need to be added to see if the AEC actually
equals the PEe after several more state-dependent learning checks.
Studies such as this are useful in helping to define just how to
combine treatments in order to achieve the maximum benefit from both
behavior therapy and pharmacotherapy. It is through these types of studies
that models of treatment can be tested so that some day interference
effects can be compensated for and only additive effects will be seen
in therapy. Continued research is necessary to achieve these results.
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Figure captions
Figure 1. Habituation - Order effect graph. Each bar represents the average
percent change from baseline for the mean scores of trials two, three,
and four per unit.
Figure 2. Exposure in the ABC. Each line represents the mean of the three
AEC units SUDS scores for that trial, and is graphed by trial latency.
Figure 3. Exposure in the PEe. Each line represents the mean of the three
PEe units SUDS scores for that trial, and is graphed by trial latency.
Figure 4. Mean SUDS scores per trial averaged over the three units in
each condition. Point values represent the SUDS scores percent change
from baseline per trial.
Figure 5. Maximum SUDS scores per trial averaged over the three units
in each condition. Point values represent the SUDS scores percent change
from baseline per trial.
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